Subscribe to RSS
DOI: 10.1055/a-1528-7261
Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients with Rheumatic Diseases Treated with Glucocorticoids
![](https://www.thieme-connect.de/media/hmr/202108/lookinside/thumbnails/2021-01-0029_10-1055-a-1528-7261-1.jpg)
Abstract
Chronic glucocorticoid therapy is associated with osteoporosis and can cause fractures in up to 50% of patients. Increased risk of fractures in patients with glucocorticoid-induced osteoporosis does not result only from the decreased bone mineral density (BMD) but also bone microarchitecture deterioration. Trabecular bone score (TBS) is a method complementary to DXA, providing additional information about trabecular bone structure. The aim of this study was to assess the clinical utility of TBS in fracture risk assessment of patients treated with glucocorticoids. Patients with rheumatic diseases treated with glucocorticoids for at least 3 months were enrolled. All recruited patients underwent DXA with additional TBS assessment. We analyzed the frequency of osteoporosis and osteoporotic fractures and assessed factors that might be associated with the risk of osteoporotic fractures. A total of 64 patients were enrolled. TBS and TBS T-score values were significantly lower in patients with osteoporosis compared to patients without osteoporosis. Low energy fractures occurred in 19 patients. The disturbed bone microarchitecture was found in 30% of patients with fractures without osteoporosis diagnosis based on BMD. In the multivariate analysis, only TBS and age were significantly associated with the occurrence of osteoporotic fractures. TBS reflects the influence of glucocorticoid therapy on bone quality better than DXA measured BMD and provides an added value to DXA in identifying the group of patients particularly prone to fractures.
Publication History
Received: 24 January 2021
Accepted after revision: 10 June 2021
Article published online:
12 August 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
References
- 1 Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112: 352-364
- 2 De Nijs RNJ. Glucocorticoid-induced osteoporosis: A review on pathophysiology and treatment options. Minerva Med 2008; 99: 23-43
- 3 Cosman F, de Beur SJ, LeBoff MS. et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014; 25: 2359-2381
- 4 Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int 2002; 13: 777-787
- 5 Krohn K, Schwartz EN, Chung YS. et al. Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position. J Clin Densitom 2019; 22: 501-505
- 6 Kanis JA, Cooper C, Rizzoli R. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30: 3-44
- 7 Ulivieri FM, Silva BC, Sardanelli F. et al. Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine 2014; 47: 435-448
- 8 Paggiosi MA, Peel NFA, Eastell R. The impact of glucocorticoid therapy on trabecular bone score in older women. Osteoporos Int 2015; 26: 1773-1780
- 9 Leslie WD, Aubry-Rozier B, Lamy O. et al. TBS (Trabecular Bone Score) and Diabetes-Related Fracture Risk. J Clin Endocrinol Metab 2013; 98: 602-609
- 10 Silva BC, Boutroy S, Zhang C. et al. Trabecular Bone Score (TBS) – A Novel Method to Evaluate Bone Microarchitectural Texture in Patients With Primary Hyperparathyroidism. J Clin Endocrinol Metab 2013; 98: 1963-1070
- 11 Rampersad C, Whitlock RH, Leslie WD. et al. Trabecular bone score in patients with chronic kidney disease. Osteoporos Int 2020; 31: 1905-1912
- 12 Leib ES, Winzenrieth R. Bone status in glucocorticoid-treated men and women. Osteoporos Int 2016; 27: 39-48
- 13 Choi YJ, Chung YS, Suh CH. et al. Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis. Medicine (Baltimore) 2017; 96: e8661
- 14 Kim HA, Lee HY, Jung JY. et al. Trabecular Bone score is a useful parameter for the prediction of vertebral fractures in patients with polymyalgia rheumatica. J Clin Densitom 2020; 23: 373-380
- 15 Kim D, Cho SK, Kim JY. et al. Association between trabecular bone score and risk factors for fractures in Korean female patients with rheumatoid arthritis. Mod Rheumatol 2016; 26: 540-545
- 16 Florez H, Hernández-Rodríguez J, Muxi A. et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatol (United Kingdom) 2020; 59: 1574-1580
- 17 TBS report Hologic. Guidance and Notes (https://www.medimapsgroup.com/doc/follow-up-report/)Accessed 3 December 2020
- 18 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1–129
- 19 McCloskey EV, Odén A, Harvey NC. et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res 2016; 31: 940-948
- 20 Torgutalp ŞS, Babayeva N, Kara ÖS. et al. Trabecular bone score of postmenopausal women is positively correlated with bone mineral density and negatively correlated with age and body mass index. Menopause 2019; 26: 1166-1170
- 21 Chuang MH, Chuang TL, Koo M. et al. Trabecular Bone Score Reflects Trabecular Microarchitecture Deterioration and Fragility Fracture in Female Adult Patients Receiving Glucocorticoid Therapy: A Pre-Post Controlled Study. Biomed Res Int 2017; 4210217
- 22 Martineau P, Leslie WD, Johansson H. et al. In which patients does lumbar spine trabecular bone score (TBS) have the largest effect?. Bone 2018; 113: 161-168